AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: In our previous publications we have shown that JAK2 regulates key signaling molecules in Bcr-Abl-driven pathways including LYN, AKT, and pTyr177 of BCR-ABL [14-16, 20], suggesting that JAK2 is a potential therapeutic target in CML [14, 15, 17, 27].